Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Performance Outlook 2026–2030: Revenue to Hit $4.94 Billion at 18.4% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the ribonucleic acid (rna)-based oncolytic therapy market from 2026–2035 with trusted insights from The Business Research Company
How is the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market size predicted to change over the forecast window of 2026–2035?
The ribonucleic acid (rna)-based oncolytic therapy market has seen considerable expansion in recent years. This market is set to increase from $2.12 billion in 2025 to $2.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 18.7%. The observed growth in previous periods can be linked to developments in cancer virology research, an enhanced grasp of tumor immunology, the availability of infrastructure for clinical trials, increased financial support for oncology research, and the initial positive results from oncolytic virus investigations.
The ribonucleic acid (rna)-based oncolytic therapy market is projected to experience substantial expansion over the upcoming years, reaching $4.94 billion by 2030, demonstrating an impressive compound annual growth rate (CAGR) of 18.4%. This anticipated growth during the forecast period is fueled by several factors, including the increasing number of approvals for rna-based cancer therapies, a rising demand for personalized oncology treatments, the expansion of immuno-oncology research and development pipelines, heightened investment in gene and cell therapies, and advancements in rna delivery systems technology. Key developments shaping the market in the forecast period encompass further progress in rna virus engineering, a growing preference for combination oncolytic therapies, increased attention on activating the immune system, the development of more targeted tumor-specific rna therapies, and improved integration of precision oncology tools.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
Which Drivers Are Contributing To The Expansion Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
The expanding uptake of personalized medicine is anticipated to drive the growth of the RNA-based oncolytic therapy market moving forward. Personalized medicine involves medical interventions customized to individual genetic profiles, which enhances their effectiveness and lessens negative reactions. The integration of personalized medicine is gaining traction as a greater number of healthcare providers and institutions acknowledge its capability to improve patient outcomes through precise therapies and targeted diagnostics. RNA-based oncolytic therapy holds a significant position in cancer treatment by aligning with the increasing acceptance of personalized medicine to deliver specific and patient-centric therapeutic strategies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. As a result, the widening adoption of personalized medicine is propelling the RNA-based oncolytic therapy market.
What Segment Categories Are Covered In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
Which Innovation Trends Are Advancing Developments Within The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Leading companies in the ribonucleic acid (RNA)-based oncolytic therapy market are dedicated to developing technological advancements like synthetic messenger RNA (mRNA) technology. This focus aims to improve tumor-targeting efficiency, enhance immune activation, and achieve more precise and durable cancer treatment outcomes. Synthetic messenger RNA (mRNA) technology is a biotechnology method that designs and delivers laboratory-made mRNA sequences, guiding cells to produce specific therapeutic proteins for treating diseases, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company from China, gained regulatory approval in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development marks a significant progression within the country’s messenger RNA therapeutics landscape. SYS6020 leverages mRNA-lipid nanoparticle technology to selectively target and eliminate myeloma cancer cells with minimal adverse effects, also showing potential for treating certain autoimmune diseases.
Which Key Market Players Are Investing In Expansion And Innovation Within The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28321&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Oncolytic Virus Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
